New chemo combo aims to make tough pancreatic tumors operable
NCT ID NCT05825066
Summary
This study is testing whether giving two different chemotherapy regimens in sequence—first Gemcitabine-Abraxane, then mFOLFIRINOX—can better shrink pancreatic tumors that are difficult or impossible to remove with surgery. The goal is to see if this approach makes successful surgery more likely and improves survival for the 64 participants. Researchers will closely monitor how well patients tolerate the treatment and track tumor response and survival outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.